Evidence map›Paper›PMID 41342346›Full record

ArticleThoracic cancer2025

Impact of Long-Term Structured Exercise on Body Composition in an NTRK Fusion-Positive NSCLC Patient Treated With Entrectinib.

Alice Avancini, Marco Sposito, Gloria Adamoli, Anita Borsati, Christian Ciurnelli, Ilaria Mariangela Scaglione, Serena Eccher, Linda Toniolo, Daniela Tregnago, Lucia Longo and 5 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Alice AvanciniSection of Oncology, Department of Engineering for Innovation Medicine (DIMI), University of Verona and Verona University Hospital Trust, Verona, Italy.ORCID https://orcid.org/0000-0003-2439-4799
Marco SpositoSection of Oncology, Department of Engineering for Innovation Medicine (DIMI), University of Verona and Verona University Hospital Trust, Verona, Italy.
Gloria AdamoliSection of Oncology, Department of Engineering for Innovation Medicine (DIMI), University of Verona and Verona University Hospital Trust, Verona, Italy.
Anita BorsatiDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Christian CiurnelliDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.ORCID https://orcid.org/0009-0006-1450-165X
Ilaria Mariangela ScaglioneSection of Oncology, Department of Engineering for Innovation Medicine (DIMI), University of Verona and Verona University Hospital Trust, Verona, Italy.
Serena EccherSection of Oncology, Department of Engineering for Innovation Medicine (DIMI), University of Verona and Verona University Hospital Trust, Verona, Italy.
Linda TonioloDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Daniela TregnagoSection of Oncology, Department of Engineering for Innovation Medicine (DIMI), University of Verona and Verona University Hospital Trust, Verona, Italy.
Lucia LongoSection of Oncology, Department of Engineering for Innovation Medicine (DIMI), University of Verona and Verona University Hospital Trust, Verona, Italy.
Jessica InsoldaSection of Oncology, Department of Engineering for Innovation Medicine (DIMI), University of Verona and Verona University Hospital Trust, Verona, Italy.
Michele MilellaSection of Oncology, Department of Engineering for Innovation Medicine (DIMI), University of Verona and Verona University Hospital Trust, Verona, Italy.
Federico SchenaDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Sara PilottoSection of Oncology, Department of Engineering for Innovation Medicine (DIMI), University of Verona and Verona University Hospital Trust, Verona, Italy.
Lorenzo BelluominiSection of Oncology, Department of Engineering for Innovation Medicine (DIMI), University of Verona and Verona University Hospital Trust, Verona, Italy.

Funding

Associazione Italiana per la Ricerca sul Cancro
6 · The paper itself

Abstract

Entrectinib, a first-generation TRK inhibitor, is effective in NTRK fusion-positive non-small cell lung cancer (NSCLC) but commonly induces significant weight gain. We describe the case of a 42-year-old patient with metastatic NTRK-positive NSCLC undergoing entrectinib who participated in a two-year, supervised exercise program. The intervention included twice-weekly aerobic and resistance training aligned with international exercise-oncology guidelines. Adherence was high (91.6%), and no exercise-related adverse events occurred. Despite an initial 13 kg weight gain over 9 months, split between fat and lean mass, subsequent fat loss (~3.5 kg) occurred while lean mass was preserved. This case suggests that prolonged, structured exercise is a safe and feasible strategy to attenuate entrectinib-associated metabolic effects and support physical function during targeted therapy in advanced NSCLC.

Indexed as

BenzamidesBody CompositionCarcinoma, Non-Small-Cell LungExerciseIndazolesLung NeoplasmsAdultHumansBenzamidesentrectinibIndazolesbody compositionentrectinibNSCLCNTRK fusionphysical exerciseweight

Identifiers

PMID41342346
PMCPMC12676302

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.